Treatment Options for Early-Stage HER2+ Breast Cancer

home / oncview / treatment-options-for-early-stage-her-2-breast-cancer

Joyce O’Shaughnessy, MD discusses a modern approach to treating patients with early-stage HER2+ breast cancer, elaborating on the entire process from the initial determination of patient eligibility to monitoring in the curative setting.

The HER2-Positive Breast Cancer Landscape

EP. 1: The HER2-Positive Breast Cancer Landscape

Joyce A. O’Shaughnessy
October 7th 2022

Joyce O’Shaughnessy, MD shares an overview of the HER2-positive breast cancer landscape, focusing on prognosis and risk of recurrence for patients with early-stage and metastatic breast cancer.

A Generalized Approach to First-Line HER2-Positive Breast Cancer Treatment

EP. 2: A Generalized Approach to First-Line HER2-Positive Breast Cancer Treatment

Joyce A. O’Shaughnessy
October 7th 2022

A breast cancer expert shares the current first-line standard of care for patients with HER2-positive breast cancer and presents scenarios where the standard treatment approach may not be appropriate.

Pertuzumab and Trastuzumab: Patient Eligibility, Administration Methods, and Dosing Strategies

EP. 3: Pertuzumab and Trastuzumab: Patient Eligibility, Administration Methods, and Dosing Strategies

Joyce A. O’Shaughnessy
October 13th 2022

Clinical insights concerning the administration of combination pertuzumab/trastuzumab/hyaluronidase-zzxf for patients with HER2-positive breast cancer.

Data Review and Key Insights: The FeDeriCa Trial and PHranceSCa Study

EP. 4: Data Review and Key Insights: The FeDeriCa Trial and PHranceSCa Study

Joyce A. O’Shaughnessy
October 13th 2022

Dr. Joyce O’Shaughnessy briefly reviews and provides insights into the FeDeriCa and the PHranceSCa studies.

The Impact of COVID-19 on Treatment Decisions Across Patients with HER2-Positive Breast Cancer

EP. 5: The Impact of COVID-19 on Treatment Decisions Across Patients with HER2-Positive Breast Cancer

Joyce A. O’Shaughnessy
October 20th 2022

Discussion centered around the how the COVID-19 pandemic has influenced clinical treatment decisions across patients with HER2-positive breast cancer.

Discussing Treatment and Management Strategies with Patients in the HER2-Positive Setting

EP. 6: Discussing Treatment and Management Strategies with Patients in the HER2-Positive Setting

Joyce A. O’Shaughnessy
October 20th 2022

Advice for clinicians on how to discuss treatment and management strategies with patients with HER2-postitive breast cancer.

Early-Stage Monitoring and Adverse Event Mitigation for Patients with HER2-Postitive Breast Cancer

EP. 7: Early-Stage Monitoring and Adverse Event Mitigation for Patients with HER2-Postitive Breast Cancer

Joyce A. O’Shaughnessy
October 27th 2022

Dr. Joyce O’Shaughnessy closes the discussion with considerations for clinicians on monitoring patients with HER2-psotive breast cancer.